Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Grant

Showing results (91-100 of 386) with videos related to

Pageof 39
Sort By:
Cancer Research|July 4, 2003
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1Roberto R Rosato, Jorge A Almenara, Steven Grant
Cell Cycle (Georgetown, Tex.)|October 7, 2004
The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cellsWesam Ahmed, Mohamed Rahmani, Paul Dent, et al.
Cancers|July 14, 2023
Secondary-Type Mutations in Acute Myeloid Leukemia: Updates from ELN 2022Ian M Bouligny, Keri R Maher, Steven Grant
Cell Cycle (Georgetown, Tex.)|February 16, 2006
Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entryYun Dai, Tracy E Hamm, Paul Dent, et al.
Zootaxa|March 23, 2021
A new arc-striped species of Corydoras Lacépède, 1803 (Teleostei: Callichthyidae) from the Peruvian AmazonRebecca Frances Bentley, Steven Grant, Luiz Fernando Caserta Tencatt
Leukemia Research|February 17, 2006
Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/AblGirija Dasmahapatra, Tri K Nguyen, Paul Dent, et al.
Expert Opinion on Pharmacotherapy|September 30, 2014
Bortezomib for the treatment of non-Hodgkin's lymphomaPrithviraj Bose, Michael S Batalo, Beata Holkova, et al.
Leukemia Research Reports|August 27, 2013
Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinasePrithviraj Bose, Haeseong Park, Jawad Al-Khafaji, et al.
Molecular Pharmacology|June 28, 2007
The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulationMohamed Rahmani, Tri K Nguyen, Paul Dent, et al.
Molecular and Cellular Biology|October 7, 2009
Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1Shuang Chen, Yun Dai, Xin-Yan Pei, et al.
Pageof 39

Showing results (91-100 of 386) with videos related to

Sort By:
Pageof 39
Cancer Research|July 4, 2003
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1Roberto R Rosato, Jorge A Almenara, Steven Grant
Cell Cycle (Georgetown, Tex.)|October 7, 2004
The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cellsWesam Ahmed, Mohamed Rahmani, Paul Dent, et al.
Cancers|July 14, 2023
Secondary-Type Mutations in Acute Myeloid Leukemia: Updates from ELN 2022Ian M Bouligny, Keri R Maher, Steven Grant
Cell Cycle (Georgetown, Tex.)|February 16, 2006
Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entryYun Dai, Tracy E Hamm, Paul Dent, et al.
Zootaxa|March 23, 2021
A new arc-striped species of Corydoras Lacépède, 1803 (Teleostei: Callichthyidae) from the Peruvian AmazonRebecca Frances Bentley, Steven Grant, Luiz Fernando Caserta Tencatt
Leukemia Research|February 17, 2006
Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/AblGirija Dasmahapatra, Tri K Nguyen, Paul Dent, et al.
Expert Opinion on Pharmacotherapy|September 30, 2014
Bortezomib for the treatment of non-Hodgkin's lymphomaPrithviraj Bose, Michael S Batalo, Beata Holkova, et al.
Leukemia Research Reports|August 27, 2013
Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinasePrithviraj Bose, Haeseong Park, Jawad Al-Khafaji, et al.
Molecular Pharmacology|June 28, 2007
The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulationMohamed Rahmani, Tri K Nguyen, Paul Dent, et al.
Molecular and Cellular Biology|October 7, 2009
Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1Shuang Chen, Yun Dai, Xin-Yan Pei, et al.
Pageof 39